Reassessing Aerie Pharmaceuticals
Summary: Today, we revisit ocular concern Aerie Pharmaceuticals. The company has struggled as a newly
Summary: Today, we revisit ocular concern Aerie Pharmaceuticals. The company has struggled as a newly
Summary: Sell-side estimates for this quarter’s revenue are too high and have begun to be
Summary: Recent “failure” of lead compound opens up new windows. Let’s talk about the pipeline;
Summary: We revisit Aerie Pharmaceuticals. The stock has had a wild ride, getting crushed in the